Park says patient-specific factors that influence his treatment selection include the presence of liver disease, ...
The FDA accepted the investigational new drug application for UGN-103 in April 2024. These new positive data position the ...
Daratumumab and hyaluronidase-fihj received FDA approval for high-risk smoldering multiple myeloma, showing significant PFS ...
Jason S. Starr, DO, assistant professor of medicine and a hematologist/oncologist in the Department of Internal Medicine at ...
In the phase 2 EDGE-Gastric trial (NCT05329766), the combination of monoclonal antibodies domvanalimab and zimberelimab ...
Regarding efficacy, the phase 1 trial showed impressive objective response rates (ORR), approaching 70%. Typical PRRT alone ...
M2T-CD33 (LTI-214) has received FDA orphan drug designation, offering incentives like tax credits and market exclusivity for AML treatment. The treatment targets CD33, a glycoprotein present in 90% of ...
A phase 1 trial reveals that combining radiotherapy with immunotherapy enhances response rates in B-cell lymphomas while maintaining manageable safety profiles.
The combination of talquetamab (Talvey) and daratumumab (Darzalex) demonstrated promising and robust clinical activity for the treatment of patients with heavily pretreated, relapsed/refractory ...
1. Huang J. Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial. Presented at: ESMO 2025 Congress; October ...
The management of advanced thyroid cancer requires careful consideration of histology, molecular profiling, and treatment ...
Iams, MD, MSCI, discussed potential ways to determine which patients benefit most from additional therapy for extensive-stage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback